Glaxo eyeing Pfizer consumer meds

Janet Babin Jun 6, 2006


MARK AUSTIN THOMAS: Final bids to purchase the over-the-counter division of New York-based Pfizer are expected today. That means ownership of brands like Sudafed, Listerine and Kaopectate could soon change hands. Pharmaceutical giant GlaxoSmithKline is the reported frontrunner. Janet Babin has more.

JANET BABIN: Pfizer’s over the counter medicines bring in about $3.8 billion a year.

That sales revenue could go a long way for GlaxoSmithKline. The British company’s been looking to expand its over-the-counter presence in the US.

Les Funtleyder is an analyst with Miller Tabak. He says Pfizer has decided to focus on branded prescription pharmaceuticals, and could use capital from the sale to develop new drugs

LES FUNTLEYDER: On the other hand, if Pfizer sells the division and is unable to deploy the capital in a way that generates returns for shareholders, people will say the deal was unsuccessful.

Funtleyder says the final price for the Pfizer unit will likely be at least $10 billion.

I’m Janet Babin for Marketplace.

We’re here to help you navigate this changed world and economy.

Our mission at Marketplace is to raise the economic intelligence of the country. It’s a tough task, but it’s never been more important.

In the past year, we’ve seen record unemployment, stimulus bills, and reddit users influencing the stock market. Marketplace helps you understand it all, will fact-based, approachable, and unbiased reporting.

Generous support from listeners and readers is what powers our nonprofit news—and your donation today will help provide this essential service. For just $5/month, you can sustain independent journalism that keeps you and thousands of others informed.